701 results on '"Kapiteijn, E."'
Search Results
2. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol
3. Correction to: Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases
4. Health-state utilities in long-term advanced melanoma survivors comparable with the general population
5. Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
6. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
7. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial
8. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
9. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
10. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
11. Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
12. Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort
13. Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort
14. A prediction model for response to immune checkpoint inhibition in advanced melanoma
15. Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21,196 patients from the Netherlands and Norway
16. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
17. A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature
18. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort
19. Endocriene tumoren
20. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
21. Adjuvant treatment with anti-PD-1 in acral melanoma: a nationwide study
22. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.
23. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
24. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
25. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.
26. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
27. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
28. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
29. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
30. Health-state utilities in long-term advanced melanoma survivors comparable with the general population
31. CT radiomics to predict checkpoint inhibitors treatment outcomes in patients with advanced cutaneous melanoma
32. 31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer
33. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
34. 849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma
35. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
36. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
37. 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
38. 812P Early experiences in adjuvant treatment of melanoma: Real-world data on tolerability, safety and efficacy
39. 860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma
40. 6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
41. Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
42. Survival of stage IV melanoma in Belgium and the Netherlands
43. Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry
44. The unfavorable effects of COVID-19 on Dutch advanced melanoma care
45. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice
46. Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry
47. Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
48. BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma
49. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
50. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.